Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways.
Synthetic glucocorticoids are potent modulators of the immune system, and are clinically invaluable in the treatment of a wide variety of conditions. However, their use can be limited by harmful side effects, and their mechanisms of action remain poorly understood and controversial. It has recently been reported that glucocorticoids induce the expression of two genes that participate in cross-talk with the mitogen-activated protein kinase signalling pathways. It is possible that both therapeutic and harmful effects of glucocorticoids may be mediated by these genes.
Clark
Andrew R
AR
Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK. andy.clark@imperial.ac.uk
Lasa
Marina
M
D000818:Animals; D017209:Apoptosis / Q000276:immunology; D002455:Cell Division / Q000276:immunology; D005786:Gene Expression Regulation; D005938:Glucocorticoids / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D015398:Signal Transduction / Q000276:immunology / Q000502:physiology*; D014157:Transcription Factors / Q000235:genetics / Q000276:immunology / Q000502:physiology; D014158:Transcription, Genetic / Q000187:drug effects
D005938:Glucocorticoids; C404226:TSC22D3 protein, human; D014157:Transcription Factors; D020928:Mitogen-Activated Protein Kinases